https://doctransparency.com/doctor/fl/bradenton/kate-gerber-1750600359
Medicare Enrolled

Dr. Kate Gerber, MD

MOHS-Micrographic Surgery Physician · Bradenton, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Speaking/Promotional
5301 4TH AVENUE CIR E, Bradenton, FL 34208
9417612900
In practice since 2010 (15 years)
NPI: 1750600359 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gerber from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gerber? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Gerber

Dr. Kate Gerber is a mohs-micrographic surgery physician in Bradenton, FL, with 15 years in practice. Based on federal Medicare data, Dr. Gerber performed 6,778 Medicare services across 4,014 unique beneficiaries.

Between the years covered by Open Payments, Dr. Gerber received a total of $15,833 from 43 pharmaceutical and/or device companies across 386 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in mohs-micrographic surgery physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Gerber is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 15 years in practice▲ Top 26% volume in FL$ $15,833 industry payments

Medicare Practice Summary

Medicare Utilization ↗
6,778
Medicare services
Top 26% in FL for mohs-micrographic surgery physician
4,014
Unique beneficiaries
$61
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~452 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Destruction of precancerous skin growths, 2-141,959$5$13
Office visit, established patient (20-29 min)956$61$179
Destruction of precancerous skin growth, 1775$33$132
Skin biopsy, tangential598$62$199
Destruction of skin growths (warts/lesions), 1-14439$77$222
Biopsy of related skin growth, each additional growth360$39$99
Office visit, established patient (30-39 min)287$84$253
Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm191$109$354
Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks161$509$1,340
Office visit, established patient (10-19 min)114$38$112
Steroid injection (triamcinolone)102$1$2
New patient office visit (30-44 min)98$69$224
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm72$96$485
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm58$214$601
Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm47$124$374
Destruction of precancer skin growth, 15 or more growths45$126$334
Administration of chemotherapy into growth, 1-745$52$163
Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks43$320$812
Injection into skin growth, 1-7 growths42$28$113
Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm41$317$845
Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm38$140$409
Methotrexate sodium, 50 mg35$2$5
Destruction of skin growth, 15 or more growths32$93$261
New patient office visit (45-59 min)31$118$333
Removal of skin tag, 1-15 skin tags30$42$181
Biopsy of ear30$57$192
Punch biopsy, first skin growth25$93$247
Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm24$71$340
Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm22$113$556
Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm20$110$382
Complicated repair of wound of trunk, 2.6-7.5 cm19$311$789
Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm14$101$501
Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm13$320$939
Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less12$132$563
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$15,833
Total received (2018-2024)
Avg $2,262/year across 7 years
Top 14% in FL for mohs-micrographic surgery physician
43
Companies
386
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$8,561 (54.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,272 (45.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,489
2023
$1,125
2022
$9,453
2021
$1,000
2020
$674
2019
$841
2018
$1,251

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Incyte Corporation
$8,182
Janssen Biotech, Inc.
$716
Regeneron Healthcare Solutions, Inc.
$647
Merz North America, Inc.
$567
ABBVIE INC.
$519
Novartis Pharmaceuticals Corporation
$506
Lilly USA, LLC
$361
LEO Pharma Inc.
$351
AbbVie Inc.
$341
GENZYME CORPORATION
$332
Biofrontera Inc.
$314
PFIZER INC.
$313
UCB, Inc.
$294
Sun Pharmaceutical Industries Inc.
$293
SUN PHARMACEUTICAL INDUSTRIES INC.
$241
AbbVie, Inc.
$226
Amgen Inc.
$198
E.R. Squibb & Sons, L.L.C.
$135
Galderma Laboratories, L.P.
$129
Kerecis Limited
$111
Smith+Nephew, Inc.
$100
Allergan, Inc.
$88
ORGANOGENESIS INC.
$75
Mayne Pharma Inc.
$73
Helsinn Therapeutics (U.S.), Inc.
$62
VYNE Pharmaceuticals Inc.
$58
Celgene Corporation
$57
Organogenesis Inc.
$57
Dermavant Sciences, Inc.
$53
Ortho Dermatologics, a division of Bausch Health US, LLC
$53
ConvaTec Inc.
$53
Smith & Nephew, Inc.
$44
Almirall LLC
$44
MERZ NORTH AMERICA, INC.
$40
Arcutis Biotherapeutics, Inc.
$39
DUSA Pharmaceuticals, Inc.
$24
MAYNE PHARMA COMMERCIAL LLC
$24
Solta Medical, a division of Bausch Health US, LLC
$23
Aclaris Therapeutics, Inc.
$22
Genentech USA, Inc.
$21
Journey Medical Corporation
$21
Sandoz Inc.
$17
Allergan Inc.
$12
Top 3 companies account for 60.3% of total payments
Associated products mentioned in payments ›
ADBRY · AFFINITY · AKLIEF · AMELUZ · AMZEEQ · Absorica LD · BLU-U · BLU-U Blue Light Photodynamic Therapy Illuminator Model 4170 · BOTOX · BOTOX COSMETIC · Bimzelx · CIBINQO · COLLAGENASE SANTYL · COSENTYX · Cimzia · Cordran · DORYX · DUOBRII · DUPIXENT · ELIDEL · ENSTILAR · EUCRISA · Erivedge · Exelderm · HUMIRA · HYRIMOZ · Humira · ILUMYA · ILUMYA (tildrakizumab-asmn) injection · INNOVAMATRIX AC · Ilumya · Kerecis Omega3 SurgiClose · LIBTAYO · NATRELLE SALINE-FILLED BREAST IMPLANTS · OPZELURA · ORACEA · Odomzo · Otezla · Puraply · Puraply Antimicrobial · REMICADE · RHOFADE · RINVOQ · SILIQ · SKYRIZI · Santyl · Seysara · Skyrizi · Sotyktu · TALTZ · TREMFYA · Tremfya · VALCHLOR · VTAMA · Winlevi · XEOMIN · ZILXI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (54%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in mohs-micrographic surgery physician and does not inherently indicate bias, but patients may wish to be aware.

Equivalent to $234 per 100 Medicare services performed
Looking for a mohs-micrographic surgery physician in Bradenton?
Compare mohs-micrographic surgery physicians in the Bradenton area by procedure volume, costs, and industry payment transparency.
Browse mohs-micrographic surgery physicians nearby

Geographic Context

MOHS-Micrographic Surgery Physicians within 10 mi
13
Per 100K population
3.1
County median income
$75,792
Nearest hospital
MANATEE MEMORIAL HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Gerber is a clinical cardiology specialist, with above-average Medicare volume (top 26% in FL), and high industry engagement (speaking/promotional, top 14%), with 15 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Gerber experienced with destruction of precancerous skin growths, 2-14?
Based on Medicare claims data, Dr. Gerber performed 1,959 destruction of precancerous skin growths, 2-14 services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gerber receive payments from pharmaceutical companies?
Yes. Dr. Gerber received a total of $15,833 from 43 companies across 386 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gerber's costs compare to other mohs-micrographic surgery physicians in Bradenton?
Dr. Gerber's average Medicare payment per service is $61. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gerber) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →